Search Clinical Trials in the EU

Duration

>20 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

121-140 of 140 trials

HER2-Expressing Ovarian Cancer: Trastuzumab Deruxtecan with Bevacizumab

We are studying a new combination treatment for patients with HER2-expressing ovarian cancer to see if it works better than standard therapy. The trial will assess safety and how well the treatments help manage the disease.

Ovarian Cancer>2 yearsConfirmation phase (III)>20 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteGynecology and ObstetricsOncology

Crohn's Disease: SAR442970 Study

We are investigating the effects of a new medication, SAR442970, on adults with moderate to severe Crohn's disease. The study aims to see if it helps improve symptoms and overall health compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteGastroenterology

Mucopolysaccharidosis Type IIIA: JR-441 Infusions

We are evaluating the safety and potential effectiveness of JR-441 infusions for patients with mucopolysaccharidosis type IIIA. This study aims to explore how well this treatment works for this rare condition.

Mucopolysaccharidosis III>2 yearsSafety phase (I)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementHematologyInternal MedicinePediatrics

Multiple Myeloma: Isatuximab Combination Therapy

We are studying a new treatment combining isatuximab with other medications for patients with newly diagnosed multiple myeloma who cannot undergo a transplant. The goal is to see how effective and safe this treatment is, and how it impacts patients' lives.

Newly Diagnosed Transplant Ineligible Multiple Myeloma>2 yearsEfficacy phase (II)>20 visits No Placebo Standard MedicinesHematologyOncology

Ozone Treatment for Numbness from Chemotherapy

We are studying whether adding ozone therapy helps reduce numbness and tingling in patients with chemotherapy-induced nerve damage. The trial also looks at how this treatment affects overall quality of life and costs.

Chemotherapy-Induced Peripheral Neuropathy6-12 monthsEfficacy phase (II)Confirmation phase (III)>20 visits Standard MedicinesInternal MedicineNeurologyOncology

Unruptured Intracranial Aneurysms: Low-Dose Aspirin and Blood Pressure Management

We are studying whether a treatment plan with low-dose aspirin and strict blood pressure control can lower the risk of aneurysm rupture or growth in patients with unruptured intracranial aneurysms. This trial compares this approach to standard care to see if it offers better outcomes.

Unruptured Intradural Aneurysm>2 yearsConfirmation phase (III)>20 visits No Placebo Standard MedicinesCardiologyNeurology

Chronic Inflammatory Demyelinating Polyneuropathy: DNTH103 Treatment Study

We are studying a new treatment called DNTH103 for adults with Chronic Inflammatory Demyelinating Polyneuropathy. The trial aims to see if it can help reduce relapses and improve overall health compared to a placebo.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementNeurology

Leukemia Treatment: Ponatinib vs. Imatinib

We are studying whether ponatinib combined with chemotherapy is as effective as imatinib for adults with Philadelphia-Chromosome positive acute lymphoblastic leukemia. The trial also evaluates treatment outcomes for patients who respond differently.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)>20 visits No Placebo Standard MedicinesHematologyOncology

Primary Plasma Cell Leukemia: New Treatment with Bortezomib and Daratumumab

We are studying a combination of medications for people with primary plasma cell leukemia to see if it improves treatment outcomes and safety. This trial will help us understand how well this new approach works compared to current treatments.

Plasma Cell Leukemia>2 yearsEfficacy phase (II)>20 visits No Placebo Standard MedicinesHematologyOncology

Chronic Hepatitis Delta: Brelovitug Treatment Study

We are studying a new medication, brelovitug, for people with chronic hepatitis delta infection. The trial aims to see if it works better than waiting for treatment and to evaluate its safety.

Hepatitis D>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHepatology

Alzheimer's Disease: MK-2214 Study

We are testing a new medication, MK-2214, in people with early Alzheimer's disease to see if it may slow the progression of brain changes. The study will also evaluate the safety of this treatment compared to a placebo.

Alzheimer's Disease>2 yearsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementNeurology

Rezafungin for Chronic Pulmonary Aspergillosis Treatment

We are studying whether rezafungin can effectively treat chronic pulmonary aspergillosis in adults with few treatment options. The trial will assess both the effectiveness and safety of this medication.

Chronic Pulmonary Aspergillosis6-12 monthsEfficacy phase (II)>20 visits No Placebo Standard Medicines Cost ReimbursementInfectious DiseasesPulmonology

Venous Leg Ulcers: EscharEx Treatment Study

We are studying whether EscharEx can help improve wound healing in people with Venous Leg Ulcers compared to a placebo. This trial aims to assess its safety and effectiveness in wound care.

Venous Leg Ulcer6-12 monthsConfirmation phase (III)>20 visits Investigational MedicinesDermatologyInternal Medicine

Narcolepsy and Idiopathic Hypersomnia: ALKS 2680 Study

We are investigating the safety and tolerability of ALKS 2680 for people with narcolepsy and idiopathic hypersomnia. The study also looks at its effects on excessive daytime sleepiness and cataplexy.

Narcolepsy and Idiopathic Hypersomnia>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteNeurology

PMM2-CDG: GLM101 Treatment Study

We are investigating whether weekly doses of GLM101 can improve movement and coordination in people with PMM2-CDG. The study will also evaluate the safety of this new treatment compared to a placebo.

Congenital Disorder of Glycosylation (CDG)6-12 monthsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementHepatologyNeurology

Ravulizumab for Pediatric IgA Nephropathy

We are studying how Ravulizumab works in children with Primary Immunoglobulin A Nephropathy. This research may help us understand its effects and safety in younger patients.

Immunoglobulin A Nephropathy6-12 monthsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Standard MedicinesNephrologyPediatrics

Chronic Obstructive Pulmonary Disease: Verekitug Study

We are investigating whether Verekitug can help people with moderate-to-severe COPD manage their symptoms and improve lung function. The study will also assess the safety and overall impact on quality of life.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsEfficacy phase (II)>20 visits Investigational Medicines Cost Reimbursement Partially RemotePulmonology

HIV-1 Prevention: MK-8527 Oral Medication

We are studying a new once-monthly pill, MK-8527, to see if it can effectively prevent HIV-1 infection compared to a daily treatment. The trial will also assess how safe and tolerable this new medication is for participants.

HIV-1>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Investigational Medicines Partially RemoteInfectious DiseasesInternal Medicine

ELA026 for Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

We are studying the effects of ELA026 on survival in patients with sHLH triggered by lymphoma. This trial will help us understand how well this treatment works and its safety.

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)3-6 monthsEfficacy phase (II)Confirmation phase (III)>20 visits No Placebo Investigational Medicines Partially RemoteHematologyInfectious Diseases

CTNNB1 Syndrome: Gene Therapy Study for Kids

We are testing a new gene therapy given through an injection in the brain for children with CTNNB1 syndrome. The study aims to see if it is safe and if it may help improve their condition.

CTNNB1 Syndrome1-2 yearsSafety phase (I)Efficacy phase (II)>20 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteNeurologyPediatrics

Search Clinical Trials in the European Union